KR102162742B1 - 자기 공명 영상화에 사용하기 위한 신규 가돌리늄 킬레이트 화합물 - Google Patents

자기 공명 영상화에 사용하기 위한 신규 가돌리늄 킬레이트 화합물 Download PDF

Info

Publication number
KR102162742B1
KR102162742B1 KR1020177037356A KR20177037356A KR102162742B1 KR 102162742 B1 KR102162742 B1 KR 102162742B1 KR 1020177037356 A KR1020177037356 A KR 1020177037356A KR 20177037356 A KR20177037356 A KR 20177037356A KR 102162742 B1 KR102162742 B1 KR 102162742B1
Authority
KR
South Korea
Prior art keywords
amino
formula
group
tris
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177037356A
Other languages
English (en)
Korean (ko)
Other versions
KR20180011264A (ko
Inventor
마르쿠스 베르거
예시카 로르케
크리스토프-슈테판 힐거
그레고어 요스트
토마스 프렌첼
데틀레프 쥘츨레
요하네스 플라체크
올라프 팡크닌
후베르투스 피치
Original Assignee
바이엘 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53396265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102162742(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 파마 악티엔게젤샤프트 filed Critical 바이엘 파마 악티엔게젤샤프트
Publication of KR20180011264A publication Critical patent/KR20180011264A/ko
Application granted granted Critical
Publication of KR102162742B1 publication Critical patent/KR102162742B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
KR1020177037356A 2015-06-04 2016-05-30 자기 공명 영상화에 사용하기 위한 신규 가돌리늄 킬레이트 화합물 Active KR102162742B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15170658.7A EP3101012A1 (en) 2015-06-04 2015-06-04 New gadolinium chelate compounds for use in magnetic resonance imaging
EP15170658.7 2015-06-04
PCT/EP2016/062105 WO2016193190A1 (en) 2015-06-04 2016-05-30 New gadolinium chelate compounds for use in magnetic resonance imaging

Publications (2)

Publication Number Publication Date
KR20180011264A KR20180011264A (ko) 2018-01-31
KR102162742B1 true KR102162742B1 (ko) 2020-10-07

Family

ID=53396265

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177037356A Active KR102162742B1 (ko) 2015-06-04 2016-05-30 자기 공명 영상화에 사용하기 위한 신규 가돌리늄 킬레이트 화합물

Country Status (42)

Country Link
US (5) US10137209B2 (enExample)
EP (3) EP3101012A1 (enExample)
JP (1) JP6703012B2 (enExample)
KR (1) KR102162742B1 (enExample)
CN (1) CN107667096B (enExample)
AR (1) AR104897A1 (enExample)
AU (1) AU2016272602B2 (enExample)
CA (1) CA2987993C (enExample)
CL (1) CL2017003083A1 (enExample)
CO (1) CO2017012490A2 (enExample)
CU (1) CU24467B1 (enExample)
CY (2) CY1122323T1 (enExample)
DK (2) DK3303307T3 (enExample)
DO (1) DOP2017000282A (enExample)
EA (1) EA033612B1 (enExample)
EC (1) ECSP17080394A (enExample)
ES (2) ES2893244T3 (enExample)
GE (1) GEP20207146B (enExample)
HR (2) HRP20211467T1 (enExample)
HU (2) HUE056328T2 (enExample)
IL (1) IL255945B (enExample)
JO (1) JO3702B1 (enExample)
LT (2) LT3611169T (enExample)
MA (2) MA43146B1 (enExample)
MX (1) MX374249B (enExample)
NI (1) NI201700149A (enExample)
NZ (1) NZ737707A (enExample)
PE (1) PE20180261A1 (enExample)
PH (1) PH12017502205B1 (enExample)
PL (2) PL3303307T3 (enExample)
PT (2) PT3611169T (enExample)
RS (2) RS59565B1 (enExample)
SA (1) SA517390476B1 (enExample)
SI (2) SI3303307T1 (enExample)
SM (1) SMT202100569T1 (enExample)
SV (1) SV2017005578A (enExample)
TN (1) TN2017000505A1 (enExample)
TW (1) TWI699358B (enExample)
UA (1) UA123313C2 (enExample)
UY (1) UY36711A (enExample)
WO (1) WO2016193190A1 (enExample)
ZA (1) ZA201800024B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240086545A (ko) * 2022-12-09 2024-06-18 재단법인 대구경북첨단의료산업진흥재단 신규한 가돌리늄계 화합물 및 이를 포함하는 mri 조영제

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) * 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
WO2019157119A1 (en) * 2018-02-07 2019-08-15 University Of Cincinnati System and method for detecting small blood-tissue barrier disruption
PE20211471A1 (es) * 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos
CN110396122B (zh) * 2019-08-13 2020-10-27 牡丹江医学院 一种核磁共振造影剂、制备方法及其用于肿瘤诊断中的用途
US20220370646A1 (en) * 2019-10-25 2022-11-24 Bracco Imaging S.P.A. Pharmaceutical compositions of gd-based contrast agents
KR102386595B1 (ko) * 2019-10-29 2022-04-14 경북대학교 산학협력단 신규한 가돌리늄계 화합물, 이의 제조 방법, 및 이를 함유하는 mri 조영제
CN111393544A (zh) * 2020-03-02 2020-07-10 合肥工业大学 一种具有靶向核磁共振造影和荧光成像功能的聚合物、制备方法及应用
KR102548998B1 (ko) * 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물
CN114181233B (zh) * 2021-11-24 2023-10-31 复旦大学 一种钆基T1磁共振造影剂FD-Gd-123及其制备方法和应用
CN114276309B (zh) * 2021-12-24 2023-08-11 南京科技职业学院 一类含乙氧基芳环的钆磁共振造影剂及其制备方法与应用
EP4581640A1 (de) 2022-08-30 2025-07-09 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046833A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
WO2024046832A1 (de) 2022-08-30 2024-03-07 Bayer Aktiengesellschaft Erzeugen von synthetischen radiologischen aufnahmen
JP2025531766A (ja) * 2022-09-05 2025-09-25 バイエル、アクチエンゲゼルシャフト 人工造影放射線画像の生成
EP4335461A1 (en) 2022-09-09 2024-03-13 Bayer AG Combinations of contrast agents
WO2024063529A1 (ko) * 2022-09-20 2024-03-28 주식회사 테라노큐어 신규 화합물 및 이를 포함하는 염증성 질환과 암에 대한 진단 및 치료에 사용되는 mri 조영제
WO2024083466A1 (de) 2022-10-17 2024-04-25 Bayer Aktiengesellschaft Automatisches analysieren von radiologischen aufnahmen
EP4360660A1 (en) 2022-10-24 2024-05-01 Bayer AG Process for the preparation of a gadolinium contrast agent
EP4369285A1 (de) 2022-11-12 2024-05-15 Bayer AG Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4369353A1 (de) 2022-11-12 2024-05-15 Bayer Aktiengesellschaft Erzeugung von künstlichen kontrastmittelverstärkten radiologischen aufnahmen
EP4471710B1 (de) 2023-05-30 2025-12-17 Bayer Aktiengesellschaft Erkennen von artefakten in synthetischen medizinischen aufnahmen
EP4475137B1 (de) 2023-06-05 2025-12-03 Bayer Aktiengesellschaft Erzeugen von künstlichen kontrastverstärkten radiologischen aufnahmen
EP4485474A3 (de) 2023-06-05 2025-04-16 Bayer AG Erzeugen von künstlichen kontrastverstärkten radiologischen aufnahmen
US20250045926A1 (en) 2023-07-25 2025-02-06 Bayer Aktiengesellschaft Detection of artifacts in synthetic images
EP4567715A1 (en) 2023-12-06 2025-06-11 Bayer Aktiengesellschaft Generating synthetic representations
EP4567716A1 (en) 2023-12-06 2025-06-11 Bayer Aktiengesellschaft Generating synthetic representations
WO2025190828A1 (en) 2024-03-15 2025-09-18 Bayer Aktiengesellschaft Correction of an mri image
EP4664393A1 (de) 2024-06-10 2025-12-17 Bayer Aktiengesellschaft Erzeugen von synthetischen kontrastverstärkten radiologischen aufnahmen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032862A1 (en) 1996-03-08 1997-09-12 Bracco S.P.A. Polychelants, their complexes with metal ions, their preparation and their uses

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4485237A (en) 1983-03-08 1984-11-27 The United States Of America As Represented By The Secretary Of The Navy Insensitive polynitramine compound
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5039512A (en) 1986-08-04 1991-08-13 Salutar, Inc. NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5138923A (en) 1988-11-18 1992-08-18 Atlas Die, Inc. Rotary die cutter
US5011925A (en) 1989-03-09 1991-04-30 Mallinckrodt, Inc. Morpholinoamido EDTA derivatives
EP0489869B1 (en) 1989-08-28 1998-11-11 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
GB9320277D0 (en) 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
ATE166864T1 (de) 1989-10-23 1998-06-15 Nycomed Salutar Inc Mehrzähnige metall-chelatierende verbindungen
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US5167942A (en) 1990-11-21 1992-12-01 Board Of Regents, The University Of Texas System Methods for the preparation of molecular sieves, including zeolites, using metal chelate complexes
US5141740A (en) 1990-11-21 1992-08-25 Mallinckrodt Medical, Inc. Complexes and compositions for magnetic resonance imaging and usage methods
WO1992009884A1 (en) 1990-11-21 1992-06-11 Mallinckrodt Medical, Inc. Alkoxyamide derivatized chelates for mri
EP0584256B1 (en) 1991-04-22 1999-11-10 Mallinckrodt Medical, Inc. Compounds and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
CA2102605A1 (en) 1991-05-23 1992-11-24 Evan C. Unger Liposoluble compounds for magnetic resonance imaging
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
CA2124329C (en) 1991-11-27 2008-11-18 Gregory A. Kopia Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
IL104059A0 (en) 1991-12-10 1993-05-13 Dow Chemical Co Bicyclopolyazamacrocyclocarboxylic acid complexes,their conjugates,processes for their preparation,and use as contrast agents
US5324503A (en) 1992-02-06 1994-06-28 Mallinckrodt Medical, Inc. Iodo-phenylated chelates for x-ray contrast
DE4232925A1 (de) 1992-09-28 1994-03-31 Diagnostikforschung Inst 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
JPH08510458A (ja) 1993-06-02 1996-11-05 ブラッコ エッセ．ピ．ア． 沃素化された常磁性キレートおよびそれらの造影剤としての使用法
IT1264690B1 (it) 1993-07-08 1996-10-04 Bracco Spa Compositi oligomeri iodurati e composizioni diagnostiche contenenti gli stessi
WO1995020353A1 (en) 1994-01-28 1995-08-03 Mallinckrodt Medical, Inc. Functionalized aza-bimacrocyclic ligands for imaging applications
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
DE4425857A1 (de) 1994-07-07 1996-01-11 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel
IL115670A (en) 1994-10-21 1999-11-30 Nihon Mediphysics Co Ltd Diagnostic imaging agent
US5672335A (en) 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US5707605A (en) 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
DE19525924A1 (de) 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
DE19549286A1 (de) 1995-12-22 1997-06-26 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE19603033A1 (de) 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19608278A1 (de) 1996-02-23 1997-08-28 Schering Ag Pharmazeutische Mittel enthaltend perfluoralkylhaltige Metallkomplexe, und ihre Verwendung in der Tumortherapie und interventioniellen Radiologie
US5866562A (en) 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
DE19652387A1 (de) 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
US6045776A (en) 1996-12-04 2000-04-04 Schering Aktiengesellschaft Process for the production of metal-complex carboxylic acid amides
US5919433A (en) 1996-12-04 1999-07-06 Schering Aktiengesellschaft Macrocyclic metal complex carboxylic acids, their use as well as process for their production
DE19652386A1 (de) 1996-12-04 1998-06-10 Schering Ag Verfahren zur Herstellung von Metallkomplexcarbonsäureamiden
DE19729013A1 (de) 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
DE19744003B4 (de) 1997-09-26 2004-07-08 Schering Ag Kontrastmittel für das Infarkt- und Nekroseimaging
EP1027077B1 (en) 1997-10-27 2003-03-05 Research Corporation Technologies, Inc Magnetic resonance imaging agents for the delivery of therapeutic agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
DE19831217A1 (de) 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
EP0998946A1 (en) 1998-08-14 2000-05-10 K.U. Leuven Research & Development Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6232265B1 (en) 1999-06-11 2001-05-15 Ibc Advanced Technologies, Inc. Particulate solid supports functionalized with polyhydroxypyridinone ligands
US6221476B1 (en) 1999-06-11 2001-04-24 Ibc Advanced Technologies, Inc. Polymeric membranes functionalized with polyhydroxypyridinone ligands
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
DE19948651B4 (de) 1999-09-29 2006-10-05 Schering Ag Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung
EP1088559A3 (de) 1999-09-29 2002-10-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Galenische Formulierungen
DE10002939C1 (de) 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
WO2001052906A2 (en) 2000-01-22 2001-07-26 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
IT1317862B1 (it) 2000-02-29 2003-07-15 Bracco Spa Coniugati di acidi biliari con chelati complessi di ioni metallici eloro uso.
IL152941A0 (en) 2000-06-21 2003-06-24 Bristol Myers Squibb Co Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same
AU2001268710A1 (en) 2000-06-21 2002-01-02 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
DE10066210B4 (de) 2000-08-11 2008-02-28 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
DE10040858C2 (de) 2000-08-11 2003-12-18 Schering Ag Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung
DE10040381C1 (de) 2000-08-11 2002-06-06 Schering Ag Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung
IL145723A0 (en) 2000-10-11 2002-07-25 Nihon Mediphysics Co Ltd Process for producing an amide compound
US20030050452A1 (en) 2000-12-26 2003-03-13 Yuji Hashiguchi Process for producing metal complex of aminooligosaccharide derivative
US20030004236A1 (en) 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
ITMI20011708A1 (it) 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
FR2836916B1 (fr) 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
US20030198597A1 (en) 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
DE10231799B4 (de) 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
US20060155120A1 (en) 2003-05-23 2006-07-13 Amedio John C Optically pure and enriched isomers of chelating ligands and contrast agents
AR047692A1 (es) 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
US7211237B2 (en) 2003-11-26 2007-05-01 3M Innovative Properties Company Solid state synthesis of lithium ion battery cathode material
DE102004023093B3 (de) 2004-05-05 2006-03-02 Schering Ag Trimere makrocyclisch substituierte Halogen-Benzolderivate
DE102004026103A1 (de) 2004-05-25 2005-12-22 Schering Ag Trimere makrocyclisch substituierte Aminoisophthalsäure-Halogen-Benzolderivate
US7988950B2 (en) 2004-07-02 2011-08-02 Bracco Imaging S.P.A. Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (MRI) which contain a chelating moiety with polyhydroxylated substituents
US8153784B2 (en) 2004-07-07 2012-04-10 The General Hospital Corporation Imaging of enzyme activity
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
US20060057071A1 (en) 2004-09-14 2006-03-16 Wing-Tak Wong Paramagnetic complexes with pendant crown compounds showing improved targeting-specificity as MRI contrast agents
US7205385B2 (en) 2004-11-12 2007-04-17 General Electric Company Polymerization method for the synthesis of polypeptide imaging agents
EP1848466A4 (en) 2005-01-31 2012-11-21 Yeda Res & Dev MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
ATE534407T1 (de) 2005-12-01 2011-12-15 Ge Healthcare As Verfahren zur dynamischen kernpolarisation (dnp) unter verwendung eines tritylrests und eines paramagnetischen metallions
WO2007064227A1 (en) 2005-12-02 2007-06-07 Ge Healthcare As Multimeric magentic resonance contrast agents
ES2393750T3 (es) 2005-12-16 2012-12-27 Ge Healthcare As Procedimiento para producir carbosilatos hiperpolarizados de aminas orgánicas
US8034898B2 (en) 2005-12-29 2011-10-11 Collagen Medical, LLC Methods of collagen imaging
US20070202047A1 (en) * 2006-01-05 2007-08-30 Markus Wolf Polyamine-substituted ligands for use as contrast agents
EP1815870A1 (en) 2006-02-01 2007-08-08 DKFZ Deutsches Krebsforschungszentrum Cyanine dye compounds linked to metal chelator for bi-modal diagnostic imaging
CA2643145C (en) 2006-02-24 2014-04-29 Mallinckrodt Inc. Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
WO2007112100A2 (en) 2006-03-24 2007-10-04 The University Of Utah Research Foundation Highly fluorinated oils and surfactants and methods of making and using same
EP1998813A2 (en) 2006-03-29 2008-12-10 GE Healthcare AS Method to produce hyperpolarised carboxylates and sulphonates in the presence of inorganic cations
WO2007111514A1 (en) 2006-03-29 2007-10-04 Ge Healthcare As Contrast agents for magnetic resonance imaging and spectroscopy consisting of a cyclic oligoamid core of 3 to 4 identical monomer units with 3 to 4 paramagnetic chelate side chains
WO2007128873A1 (en) 2006-05-05 2007-11-15 Wallac Oy A method for the preparation of maleimido derivatives of biomolecule labeling reactants and conjugates derived thereof
DE102006021495A1 (de) 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
GT200700046A (es) 2006-06-08 2008-02-01 Syngenta Ltd Nuevos microbiocidas
JP2008012596A (ja) 2006-07-03 2008-01-24 Aji Kk 把持装置
US9127130B2 (en) * 2006-08-11 2015-09-08 Starpharma Pty Ltd. Polylysine dendrimer contrast agent
CN101528124A (zh) 2006-08-17 2009-09-09 艾佩斯制药公司 用于淋巴系统成像的方法
DE102007002726A1 (de) 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
EP1980251A1 (en) 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
WO2009013350A2 (en) 2007-07-26 2009-01-29 Ge Healthcare Uk Limited Imaging medium comprising hyperpolarised 13 c-lactate and use thereof
US20110250138A1 (en) 2007-08-01 2011-10-13 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
ES2375083T3 (es) 2007-08-27 2012-02-24 Ge Healthcare Limited Medio de formación de imagen que comprende 13c-acetat-hiperpolarizado y uso del mismo.
CA2698622A1 (en) 2007-09-07 2009-03-12 Ge Healthcare Limited Method of determination of pdh activity and imaging media for use in said method
EP2042491A1 (de) 2007-09-14 2009-04-01 Bayer CropScience AG Pyridazine als Fungizide
FR2921929B1 (fr) 2007-10-08 2013-01-11 Commissariat Energie Atomique Procede de preparation de materiaux polymeriques dopes par des elements metalliques et materiaux obtenus par ce procede
DE102007058220A1 (de) 2007-12-03 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Dimere macrocyclisch substituierte Benzolderivate
EP2902041A1 (en) 2007-12-19 2015-08-05 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
WO2009080739A1 (en) 2007-12-21 2009-07-02 Ge Healthcare Limited Mr imaging agent, imaging medium and methods of imaging wherein such an imaging medium is used
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
US8545813B2 (en) 2008-01-25 2013-10-01 Northwestern University Pre-templated macromolecular architectures with multiple Gd(III) complexes and methods of use as MRI contrast agents
WO2009098192A1 (en) 2008-02-04 2009-08-13 Ge Healthcare Limited Mr imaging agent or medium compressing hzperpolarised 13c alanine and methods of imaging wherein such an imaging medium is used
CN101932340A (zh) 2008-02-04 2010-12-29 通用电气健康护理有限公司 生产超极化的氨基酸和氨基磺酸的方法
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US20110038805A1 (en) 2008-04-18 2011-02-17 Andreas Meijer Compounds comprising paramagnetic chelates arranged around a central core and their use in magneto resonance imaging and spectroscopy
CN102076214A (zh) 2008-05-19 2011-05-25 伯拉考成像股份公司 释放胃泌素的肽化合物
JP2010034528A (ja) 2008-06-23 2010-02-12 Sumitomo Chemical Co Ltd 組成物及び該組成物を用いてなる発光素子
EP2149567A1 (en) 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
JP6013735B2 (ja) 2008-09-30 2016-10-25 マリンクロット ニュークリア メディシン エルエルシー 画像目的のためのヘキソースおよび金属配位結合化合物の結合体
US20110217241A1 (en) 2008-11-14 2011-09-08 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
FR2939318B1 (fr) 2008-12-10 2012-07-13 Guerbet Sa Systeme d'encapsulation pour imagerie cest avec quelate q superieur ou egal a 2
CA2755965C (en) 2009-03-19 2019-04-16 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
US20110081428A1 (en) 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
DE102009053171B4 (de) 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
NO331773B1 (no) 2009-12-18 2012-03-26 Ge Healthcare As Mangankelater, sammensetninger omfattende slike og anvendelse av disse som kontrastmidler for magnettomografi (MR)
WO2011088193A2 (en) 2010-01-13 2011-07-21 University Of Medicine And Dentistry Of New Jersey Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
GB201004739D0 (en) 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
WO2011124672A1 (en) 2010-04-08 2011-10-13 Bracco Imaging Spa Process for preparing hyperpolarized substrates and method for mri
EP2397466B1 (en) 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
KR101236142B1 (ko) * 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
EP2457594A1 (en) 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
US9011816B2 (en) 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
CA2833587A1 (en) 2011-04-20 2012-10-26 Rf Therapeutics Inc. Targeted contrast agents and uses thereof
WO2012143355A1 (en) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Preparation of high-purity gadobutrol
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
CN102973955B (zh) 2011-09-06 2016-03-23 中国科学院福建物质结构研究所 一种含三价铝的磁共振成像造影剂
CN102442996B (zh) 2011-09-16 2014-09-24 中山大学附属第一医院 多胺类小分子显像剂、其生产方法及其应用
ES2414291B2 (es) 2011-12-16 2014-02-13 Universitat De Valencia Compuestos macrocíclicos de tipo escorpiando y su uso como antiparasitarios.
KR101336071B1 (ko) 2012-01-04 2013-12-05 한국원자력의학원 암 진단용 ｍｒｉ／ｃｔ 이중 조영제 및 그 제조방법
CN102614531B (zh) 2012-04-06 2013-06-05 中国科学院长春应用化学研究所 以二乙酰基苯或三乙酰基苯为连接体的多核非离子型磁共振成像造影剂
US9585975B2 (en) 2012-04-27 2017-03-07 Northwestern University MRI contrast agents
ES2800288T3 (es) 2012-06-20 2020-12-29 Basf Se Mezclas plaguicidas que comprenden un compuesto de pirazol
KR101456233B1 (ko) 2012-08-09 2014-11-04 한국원자력의학원 아미노시클로펜탄카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｍｒｉ 조영제
KR101456234B1 (ko) 2012-08-09 2014-11-04 한국원자력의학원 아미노시클로헥산카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｍｒｉ 조영제
KR102314293B1 (ko) 2012-09-25 2021-10-19 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드. Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제
US20150297761A1 (en) 2012-11-12 2015-10-22 The General Hospital Corporation Peptidic structures incorporating an amino acid metal complex and applications in magnetic resonance imaging
ES2648096T3 (es) 2013-01-14 2017-12-28 Molecular Insight Pharmaceuticals, Inc. Radiofármacos a base de triazina y agentes de radioformación de imágenes
US20160008490A1 (en) * 2013-02-12 2016-01-14 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
JP6608805B2 (ja) 2013-04-26 2019-11-20 ゲルベ 造影製剤および関連する調製方法
US9463254B2 (en) 2013-06-07 2016-10-11 The Board Of Regents Of The University Of Texas System Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI
CN103554185A (zh) 2013-07-04 2014-02-05 上海工程技术大学 一类大环多胺类多齿配体及其合成方法
EP2873679A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
CN103611171B (zh) 2013-11-25 2015-03-25 中国科学院长春应用化学研究所 以四苯酰基甲烷为连接体的非离子型多核磁共振成像造影剂及其制备方法
CN106660943B (zh) 2014-05-06 2020-03-17 约翰霍普金斯大学 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
US11324827B2 (en) 2014-10-01 2022-05-10 Xiamen Sinopeg Biotech Co., Ltd. Multifunctionalized polyethylene glycol derivative and preparation method therefor
US20180221513A1 (en) 2015-03-16 2018-08-09 Northwestern University Contrast-agent-labeled peptide amphiphile nanofibers
EP3101012A1 (en) * 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20160375155A1 (en) 2015-06-29 2016-12-29 Collagen Medical, LLC Collagen Imaging Compositions
WO2017030728A1 (en) 2015-08-17 2017-02-23 Southwestern Oklahoma State University Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same
WO2017093336A1 (en) 2015-11-30 2017-06-08 Ge Healthcare As Formulations comprising a combination of mri contrast agents
FI3753929T3 (fi) 2015-12-10 2023-01-31 Dimeerisiä varjoaineita
KR102703312B1 (ko) 2015-12-10 2024-09-05 브라코 이미징 에스.피.에이. 조영제
US10656229B2 (en) 2016-04-06 2020-05-19 Northwestern University Magnetic barcode imaging
WO2017178301A1 (en) 2016-04-13 2017-10-19 Bracco Imaging Spa Contrast agents
WO2018096082A1 (en) * 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CN109963838B (zh) 2016-12-12 2023-04-11 伯拉考成像股份公司 二聚造影剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032862A1 (en) 1996-03-08 1997-09-12 Bracco S.P.A. Polychelants, their complexes with metal ions, their preparation and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Contrast Media and Molecular Imaging. 2013, Vol. 8, No. 6, pp. 475-486

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240086545A (ko) * 2022-12-09 2024-06-18 재단법인 대구경북첨단의료산업진흥재단 신규한 가돌리늄계 화합물 및 이를 포함하는 mri 조영제
KR102875030B1 (ko) 2022-12-09 2025-10-22 재단법인 대구경북첨단의료산업진흥재단 신규한 가돌리늄계 화합물 및 이를 포함하는 mri 조영제

Also Published As

Publication number Publication date
EP3101012A1 (en) 2016-12-07
US20230113481A1 (en) 2023-04-13
AR104897A1 (es) 2017-08-23
AU2016272602A2 (en) 2018-04-19
EA201792675A1 (ru) 2018-05-31
MA43146B1 (fr) 2020-01-31
EP3303307A1 (en) 2018-04-11
HRP20191631T1 (hr) 2019-12-13
ES2893244T3 (es) 2022-02-08
ECSP17080394A (es) 2018-01-31
PL3303307T3 (pl) 2020-04-30
CL2017003083A1 (es) 2018-05-25
CY1122323T1 (el) 2021-01-27
CN107667096B (zh) 2021-02-02
HUE056328T2 (hu) 2022-02-28
PH12017502205A1 (en) 2018-06-11
RS62353B1 (sr) 2021-10-29
US20250114485A1 (en) 2025-04-10
PE20180261A1 (es) 2018-02-05
US20180169274A1 (en) 2018-06-21
GEP20207146B (en) 2020-09-10
EP3303307B1 (en) 2019-09-04
HUE045967T2 (hu) 2020-01-28
SMT202100569T1 (it) 2021-11-12
BR112017026135A2 (pt) 2018-08-28
MX2017015669A (es) 2018-04-18
ZA201800024B (en) 2022-05-25
ES2756703T3 (es) 2020-04-27
DOP2017000282A (es) 2017-12-31
JO3702B1 (ar) 2021-01-31
WO2016193190A1 (en) 2016-12-08
CA2987993A1 (en) 2016-12-08
HK1246281A1 (zh) 2018-09-07
US10722601B2 (en) 2020-07-28
US10137209B2 (en) 2018-11-27
US12478696B2 (en) 2025-11-25
UY36711A (es) 2016-12-30
SI3303307T1 (sl) 2019-11-29
DK3303307T3 (da) 2019-11-25
NI201700149A (es) 2018-04-11
CU24467B1 (es) 2020-01-03
IL255945A (en) 2018-01-31
KR20180011264A (ko) 2018-01-31
US20200353104A1 (en) 2020-11-12
SA517390476B1 (ar) 2020-05-11
CU20170155A7 (es) 2018-04-03
CA2987993C (en) 2021-08-31
TN2017000505A1 (en) 2019-04-12
US11491245B2 (en) 2022-11-08
UA123313C2 (uk) 2021-03-17
RS59565B1 (sr) 2019-12-31
PT3611169T (pt) 2021-10-06
MA50918B1 (fr) 2021-12-31
DK3611169T3 (da) 2021-10-11
PH12017502205B1 (en) 2022-11-16
SI3611169T1 (sl) 2021-11-30
EP3611169B1 (en) 2021-07-21
JP2018521017A (ja) 2018-08-02
MA50918A (fr) 2021-03-17
AU2016272602B2 (en) 2020-04-30
PT3303307T (pt) 2019-11-25
LT3611169T (lt) 2021-10-11
LT3303307T (lt) 2019-11-11
NZ737707A (en) 2022-11-25
TWI699358B (zh) 2020-07-21
TW201708198A (zh) 2017-03-01
IL255945B (en) 2020-02-27
EP3611169A1 (en) 2020-02-19
US20190083659A1 (en) 2019-03-21
CY1124544T1 (el) 2022-07-22
PL3611169T3 (pl) 2021-12-27
MX374249B (es) 2025-03-05
SV2017005578A (es) 2018-05-29
JP6703012B2 (ja) 2020-06-03
HRP20211467T1 (hr) 2021-12-24
AU2016272602A1 (en) 2017-12-14
CN107667096A (zh) 2018-02-06
CO2017012490A2 (es) 2018-03-09
EA033612B1 (ru) 2019-11-08

Similar Documents

Publication Publication Date Title
US12478696B2 (en) Gadolinium chelate compounds for use in magnetic resonance imaging
US11814369B2 (en) High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
HK1246281B (zh) 用於磁共振成像的新型钆螯合物化合物
BR112017026135B1 (pt) Compostos de quelato de gadolínio, seus intermediários, seus usos e seu método de preparação, e método para geração de imagem de tecido corporal em um paciente

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6